Abstract
Animal studies have indicated that technetium-99m l,l-ethylenedicysteine (99mTc-l,l-EC) may be a promising tracer agent for renal function studies. We have performed a paired study with 99mTc-mercaptoacetyltriglycine (99mTc-MAG3) and 99mTc-l,l-EC in six male volunteers. In both cases, iodine-131-labelled o-iodohippurate was co-injected as an internal biological standard. The analog images between 0 and 30 min p.i. were of identical diagnostic value for both tracer agents. The two renograms were similar in all volunteers. The mean 1-h plasma clearance for 99mTc-MAG3 and 99 mTc-l,l-EC was significantly different, respectively 382.9 ± 17.1 ml/min per 1.73 m2 versus 460.2 ± 47.7 ml/min per 1.73 m2 (P<0.003). The urinary excretion after 30 min p.i. was 69.4% ± 5.6% of the injected dose for 99mTc-MAG3 versus 66.5% ± 2.5% for 99mTc-l,l-EC (P>0.05) and after 60 min p.i. respectively 83.1% ± 3.9% versus 79.8 % ± 4.3 % (P > 0.05). 99mTc-l,l-EC has a very low plasma protein binding (31% ± 6.8%) as compared to 99mTc-MAG3 (88% ± 5.2%) and a larger volume of distribution. Although the exact mechanism responsible for the high plasma clearance of 99mTc-l,l-EC is not yet fully known, we conclude that this new agent merits further clinical evaluation in patients to establish its value as a renal radiopharmaceutical.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Tubis M, Posnick E, Nordyke RA. Preparation and use of I131 labeled sodium iodohippurate in kidney function tests. Proc Soc Exp Biol Med 1960; 103:497–498.
Davison A, Jones AG, Orvig C, Sohn Ma. A new class of oxotechnetium (V+) chelate complexes containing a TcON2S2 core. Inorg Chem 1980;20:1629–1632.
Fritzberg AR. Current status on renal radiopharmaceuticals. J Nucl Med Technol 1984; 12:177–188.
Fritzberg AR. Advances in renal radiopharmaceuticals. In: Fritzberg AR, ed. Radiopharmaceuticals: Progress and clinical perspectives. Florida: CRC Press; 1986:61–87.
Meldolesi U, Morotti A, La Cava G. 99mTc-radiopharmaceuticals in nephro-urology: current status and new trends. In: Nicolini M, Bandoli G, Mazzi U, eds. Technetium in chemistry and nuclear medicine 2. Verona: Cortina International; 1986:337–341.
Dewanjee MK. The chemistry of 99mTc-labeled radiopharmaceuticals. Semin Nucl Med 1990;20:5–27.
Verbruggen AM, De Roo MJK. Renal radiopharmaceuticals. In: Nunn AD, ed. Radiopharmaceuticals. Chemistry and pharmacolaogy. New York Basel Hong Kong: Dekker;1992:365–430.
Fritzberg AR, Klingensmith III WC, Whitney WP, Kuni CC. Chemical and biological studies of Tc-99m N,N′-bis(mercaptoa-cetamido)-ethylenediamine: a potential replacement for I-131 iodohippurate. J Nucl Med 1981;22:258–263.
Verbruggen AM, Nosco DL, Van Nerom CG, Bormans GM, Adriaens PJ, De Roo MJ. Technetium-99m-l,l-ethylenedicysteine: A renal imaging agent. I. Labeling and evaluation in animals. J Nucl Med 1992; 33: 551–557.
Crombez D, Van Nerom C, Bormans G, De Roo M, Verbruggen A. Comparison of purity and biological behaviour in mice of kit-formulated and HPLC-purified Tc-99m MAG3. In: Schmidt HAE, van der Schoot JB, eds. Nuclear medicine. The state of the art of nuclear medicine in Europe. Stuttgart: Schattauer; 1991:127–129.
Sapirstein LA, Vidt DG, Mandel MJ, Hanusek G. Volumes of distribution and clearances of intravenously injected creatinine in the dog. Am J Physiol 1955;181: 330–336.
Taylor A, Eshima D, Christian PE, Milton W. Evaluation of Tc-99m mercaptoacetyltriglycine in patients with impaired renal function. Radiology 1987;162: 365–370.
Bubeck B, Brandau W, Steinbächer M, Reinhold F, Dreikorn K, Eisenhut M, Georgi P. Technetium-99m labeled renal function and imaging agents. II. Clinical evaluation of 99mTc-MAG3 (99mTc mercaptoacetylglycylglycylglycine). Nucl Med Biol 1988;15:109–118.
Taylor A, Ziffer JA, Stevens A, Eshima D, Delaney VB, Welchel JD. Clinical comparison of 1–131 orthoiodohippurate and the kit formulation of Tc-99m mercaptoacetyltriglycine. Radiology 1989;170:721–725.
Russell CD, Thorstad B, Yester MV, Stutzman, Bakter T, Dubovsky EV Comparison of technetium-99m MAG3 with iodine-131 hippuran by a simultaneous dual channel technique. J Nucl Med 1988; 29:1189–1193.
Jafri RA, Britton KE, Nimmon CC, Solanki K, Al-Nahhas A, Bomanji J, Fettich J, Hawkins L. Technetium-99m MAG3, a comparison with iodine-123 and iodine-131 orthoiodohippurate, in patients with renal disorders. J Nucl Med 1988; 29:147–158.
Eshima D, Fritzberg AR, Taylor A. 99mTc renal function agents: current status. Semin Nucl Med 1990;20:28–40.
Bubeck B, Brandau W, Weber E, Kälbe T, Parekh N, Georgi P. Pharmacokinetics of technetium-99m-MAG3 in humans. J Nucl Med 1990; 31:1285–1293.
Müller-Suur R, Magnusson G, Boi-Svensson I, Jansson B. Estimation of technetium 99m-mercaptoacetyltriglycine plasma clearance by use of one single plasma sample. Eur J Nucl Med 1991;18:28–31.
Prenen JAC, de Klerk JMH. van het Schip AD, van Rijk PP. Technetium-99m-MAG3 versus iodine-123-OIH: renal clearance and distribution volume as measured by a constant infusion technique. J Nucl Med 1991; 32:2057–2060.
Bormans G, Cleynhens BJ, De Roo MJK, Verbruggen AM. Evaluation of the renal excretion characteristics of technetium-99m mercaptoacetyl-glycyl-d-alanylglycine in healthy volunteers. Eur J Nucl Med 1992;19:271–277.
Schaap GH, Alferink THR, de Jong RBJ, Oe PL, Roos JC, Donker AJM. 99mTc-MAG3: dynamic studies in patients with renal disease. Eur J Nucl Med 1988;14:28–31.
Russell CD, Thorstadt BL, Yeaster MV, Stutzman M, Dubovsky EV. Quantitation of renal function with technetium-99m MAG3. J Nucl Med 1988;29:1931–1933.
Kengen RA, Meijer S, Beekhuis H, Piers DA. Technetium-99m-MAG3 clearance as a parameter of effective renal plasma flow in patients with proteinuria and lowered serum albumin levels. J Nucl Med 1991; 32:1709–1712.
Jamar F, Stoffel M, Van Nerom C, Verbruggen A, Mourad M, Squifflet JP, Beckers C. Clinical evaluation of Tc-99m-l,l-ethylenedicysteine, a new renal tracer, in transplanted patients. J Nucl Med 1993; 34:129P.
Benet LZ. Pharmacokinetics: absorption, distribution and excretion. In: Katzung BG, ed. Basic and clinical pharmacology. Los Altos: Lange Medical; 1982:22–23
Russell CD, Dubovsky EV. Quantitation of renal function using MAG3 [editorial]. J Nucl Med 1991; 32:2061–2063.
Bubeck B, Brandau W, Reinbold F, Dreikorn K, Steinbächer M, Eisenhut M, Georgi P. Technetium-99m labeled renal function and imaging agents. I. Clinical evaluation of (99mTcCO2-DADS-A 99mTc N,N′-bis-(mercaptoacetyl)-2,3-diamino-propanoate). Nucl Med Biol 1988; 15:99–108.
Author information
Authors and Affiliations
Additional information
Correspondence to: A. Verbruggen
Rights and permissions
About this article
Cite this article
Van Nerom, C.G., Bormans, G.M., De Roo, M.J. et al. First experience in healthy volunteers with technetium-99m l,l-ethylenedicysteine, a new renal imaging agent. Eur J Nucl Med 20, 738–746 (1993). https://doi.org/10.1007/BF00180902
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00180902